Showing 341-350 of 5059 results for "".
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Recurrence in Patients with Thin Melanomas Linked with Poor Prognosis, Despite Rarityhttps://practicaldermatology.com/news/recurrence-patients-thin-melanomas-linked-poor-prognosis-despite-rarity/2467070/While rare, the recurrence of melanomas in patients with thin melanomas was linked with poorer prognosis and lower survival rates, a single-center analysis reported. "The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm)," the researchers wrote in their study, publi
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Roflumilast Cream 0.3% Improves Patient-Reported Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/patient-reported-outcomes-improve-roflumilast-cream-03-psoriasis/2466998/A recent study suggested efficacy for roflumilast cream 0.3% for the topical treatment of plaque psoriasis. Researchers for the study pooled data from two Phase 3 clinical trials (DERMIS-1 and DERMIS-2), which included patients aged ≥2 years with plaque psoriasis affecting between 2% and
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Studyhttps://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC). Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into th
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1]